The Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Reducing Repeated Heart Failure Rehospitalizations Among Elderly Patients With Acute Decompensated Heart Failure: The ROSES-HF Study

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have shown efficacy in reducing heart failure (HF) hospitalizations and cardiovascular mortality in patients with chronic heart failure, across a range of ejection fractions. However, data on their long-term efficacy in preventing recurrent hospital...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:The American journal of cardiology Ročník 255; s. 49 - 54
Hlavní autori: Amioka, Michitaka, Kinoshita, Hiroki, Fuji, Yuto, Nitta, Kazuhiro, Yamane, Kenichi, Shokawa, Tomoki, Nakano, Yukiko
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: United States Elsevier Inc 15.11.2025
Elsevier Limited
Predmet:
cardiovascular death
Cardiovascular diseases
Congestive heart failure
Death
Diabetes
Diuretics
Effectiveness
Ejection fraction
Failure
Glucose
Heart failure
Hospitalization
Hospitals
Inhibitors
Medical prognosis
Mortality
Older people
Patients
Rank tests
repeated rehospitalization
Sodium
Sodium-glucose cotransporter
sodium-glucose cotransporter 2 inhibitors
Therapy
sodium-glucose cotransporter 2 inhibitors
heart failure
repeated rehospitalization
cardiovascular death
ejection fraction
ISSN:0002-9149, 1879-1913, 1879-1913
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have shown efficacy in reducing heart failure (HF) hospitalizations and cardiovascular mortality in patients with chronic heart failure, across a range of ejection fractions. However, data on their long-term efficacy in preventing recurrent hospitalization after acute decompensated heart failure (ADHF) in elderly patients are limited. This study aimed to assess the long-term effect of SGLT2i on recurrent HF hospitalization in patients aged ≥75 years following their initial ADHF admission. The ROSES-HF study, a multicenter, prospective observational cohort study, enrolled 415 patients aged ≥75 years hospitalized with ADHF. Patients were divided into those receiving conventional medical therapy (without SGLT2i, n = 206) or SGLT2i therapy (n = 209), initiated at a median of 2.1 days postadmission. The incidence of recurrent HF hospitalization and the composite endpoint of HF hospitalization or cardiovascular death were compared. During a mean follow-up of 22.4 months, HF rehospitalization occurred in 65 patients (31.6%) in the conventional therapy group compared to 43 patients (20.6%) in the SGLT2i group, with a significant difference (log-rank test, p = 0.028). The cumulative annualized HF rehospitalization events were 24.1 per 100 person-years in the conventional therapy group versus 15.7 per 100 person-years in the SGLT2i group (p = 0.007). The composite endpoint of HF rehospitalization or cardiovascular death was observed in 77 patients (37.4%) in the conventional group compared to 49 patients (23.4%) in the SGLT2i group (log-rank test, p = 0.017). In conclusion, initiating SGLT2i in elderly patients post-ADHF reduces recurrent HF rehospitalization, underscoring its therapeutic value in this population.
Bibliografia:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:0002-9149
1879-1913
1879-1913
DOI:10.1016/j.amjcard.2025.07.005